

Buy	Value Indicators:	EUR	Warburg Risk Score:	0.8	Description:
	DCF:	19.00	Balance Sheet Score:	1.5	Leading supplier of specialty adhesives, UV/IR radiation systems and UV specialty lamps
	FCF-Value Potential 27e:	11.30	Market Liquidity Score:	0.0	
EUR 19.00					
Price	Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):
	Market cap:	49.7	Freefloat	74.40 %	2024/25e
	No. of shares (m):	6.1	Peter Möhrle Holding	25.60 %	Beta: 1.4
	EV:	98.0	Lazard	4.00 %	Price / Book: 0.6 x
Upside	Freefloat MC:	37.0			Equity Ratio: 51 %
131.7 %	Ø Trad. Vol. (30d):	37.68 th			Net Fin. Debt / EBITDA: 8.1 x
					Net Debt / EBITDA: 8.9 x

Change in the CEO position


Dr. Höhle announced that CEO Dr. Markus Arendt was removed from the management board effective September 14. The current chairman of the supervisory board Dr. Franz Richter was appointed as successor effective October 1.

The change is due to differing views on the strategic direction and priorities of the group. The generally weaker-than-expected operating development in the recent past (Höhle cut its FY guidance with the Q3 reporting in August) is likely to have contributed to the decision.

Dr. Richter joined Höhle's supervisory board in early 2023 and already served as interim CEO from May 2023 to April 2024, before Markus Arendt took over. Considering his strong management experience and knowledge of the company, it is believed that he can provide the right impetus for an accelerated execution of strategic priorities.

Höhle issued mid-term targets in January 2025. As the overall strategic direction and prospects of its three core segments are not expected to change, the targets should remain untouched (which are not fully baked into the forecasts anyway). The company already implemented cost-saving measures, which led to a slight improvement in profitability despite unfavourable top-line development.

While the change in the CEO position comes as a surprise, Dr. Richter is expected to pursue the strategic priorities with the aim of strengthening growth and profitability. The expectation remains unchanged that top-line growth should return to positive territory in the upcoming FY 2025/26, providing the basis for higher margins. The Buy rating and PT of EUR 19 are maintained.




Rel. Performance vs CDAX:

1 month:	1.1 %
6 months:	-11.3 %
Year to date:	-5.9 %
Trailing 12 months:	-52.5 %

Company events:


FY End: 30.9. in EUR m	CAGR (23/24-26/27e)	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Sales	4.4 %	115.2	116.1	106.3	98.7	93.5	102.0	112.5
Change Sales yoy	22.7 %	0.8 %	-8.4 %	-7.2 %	-5.3 %	9.1 %	10.3 %	
<i>Gross profit margin</i>	60.2 %	54.6 %	50.2 %	58.7 %	62.5 %	62.5 %	63.6 %	
EBITDA	64.2 %	13.8	12.1	0.4	3.1	5.4	8.7	13.7
EBIT	-	0.3	5.8	-9.4	-10.3	-0.1	2.8	7.1
EBIT adj.		7.8	11.7	7.1	0.0	-0.1	2.8	7.1
Margin	6.8 %	10.1 %	6.6 %	0.0 %	-0.1 %	2.7 %	6.3 %	
Net income	-	-4.9	-13.4	-11.1	-13.3	-1.6	0.7	4.0
EPS	-	-0.81	-2.20	-1.84	-2.19	-0.26	0.12	0.66
EPS adj.	-	0.45	-1.23	0.88	-0.54	-0.26	0.12	0.66
DPS	-	0.20	0.00	0.00	0.00	0.00	0.10	0.15
Dividend Yield	0.4 %	n.a.	n.a.	n.a.	n.a.	1.2 %	1.8 %	
FCFPS	-2.67	-3.31	0.03	0.59	0.30	0.19	0.44	
FCF / Market cap	-5.3 %	-10.9 %	0.2 %	3.4 %	3.6 %	2.3 %	5.4 %	
EV / Sales	3.1 x	2.1 x	1.6 x	1.6 x	1.0 x	1.0 x	0.8 x	
EV / EBITDA	25.6 x	19.8 x	426.3 x	50.6 x	18.0 x	11.1 x	6.9 x	
EV / EBIT	n.a.	41.1 x	n.a.	n.a.	n.a.	35.0 x	13.3 x	
P / E	n.a.	n.a.	n.a.	n.a.	n.a.	68.3 x	12.4 x	
P / E adj.	111.1 x	n.a.	22.3 x	n.a.	n.a.	68.3 x	12.4 x	
FCF Potential Yield	1.9 %	-3.5 %	2.9 %	-1.3 %	3.1 %	5.5 %	9.5 %	
Net Debt	50.1	56.3	50.7	50.1	48.3	47.2	45.1	
ROCE (NOPAT)	1.4 %	2.3 %	n.a.	n.a.	n.a.	1.6 %	4.0 %	
Guidance:	2025: Sales EUR 92-94; adj. EBITDA EUR 5-6m							

Sales development in EUR m




Source: Warburg Research

Sales by regions 2024; in %



Source: Warburg Research

Development Equipment + Systems Sales and EBIT in EUR m



Source: Warburg Research


Company Background

- With sales of more than EUR 130m, Dr. Höne is active in the areas of UV/IR Systems, specialty adhesives, quartz glass products and IR lamps. The company employs > 600 people.
- The company's activities were clearly expanded partly by acquisitions, which strengthened the core business as well as ancillary areas like (UV) adhesives or quartz glass.
- UV technology is used in a wide number of industrial applications. The most important areas of application are paint and lacquer drying, adhesives, and coating and laminating procedures.
- Meanwhile a good one-third of revenues are generated with specialty adhesives, which are predominantly used in the electronics industry.
- The customer structure is largely fragmented with the exception of a few larger customers. The top 5 customers account for roughly 20% of group sales.

Competitive Quality


- The competitive structure is characterised by a high number of smaller mainly regionally-active suppliers and just a handful of larger companies.
- Competitors of a comparable size normally serve only part of the market segments, resulting in a comparatively moderate competitive intensity within the individual segments.
- Established customer relationships present a significant barrier to market entry. UV components seldom account for more than 5-10% of the material costs, which lowers customers' motivation to switch supplier.
- With high vertical integration, Dr. Höne generates a large part of the value creation in the company.
- This allows the company to achieve higher margins and higher cash flows. The strong competitive quality is expressed in an ROCE of >15%.

Development Adhesives Sales and EBIT in EUR m




Source: Warburg Research

Sales by segments 2024; in %



Source: Warburg Research

Development Glass + Lamps Sales and EBIT in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period						Transitional period						Term. Value	
	24/25e	25/26e	26/27e	27/28e	28/29e	29/30e	30/31e	31/32e	32/33e	33/34e	34/35e	35/36e	36/37e	
Sales	93.5	102.0	112.5	121.5	128.8	136.5	143.3	150.5	158.0	164.4	170.9	177.8	180.9	
Sales change	-5.3 %	9.1 %	10.3 %	8.0 %	6.0 %	6.0 %	5.0 %	5.0 %	5.0 %	4.0 %	4.0 %	4.0 %	1.8 %	1.8 %
EBIT	-0.1	2.8	7.1	10.9	15.5	17.1	17.9	18.8	19.8	20.5	21.4	22.2	22.6	
EBIT/margin	-0.1 %	2.7 %	6.3 %	9.0 %	12.0 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %
Tax rate (EBT)	29.0 %	29.0 %	29.0 %	29.0 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %	29.5 %
NOPAT	-0.1	2.0	5.0	7.8	10.9	12.0	12.6	13.3	13.9	14.5	15.1	15.7	15.9	
Depreciation in % of Sales	5.6	6.0	6.6	7.3	7.4	5.9	6.2	6.3	6.5	6.6	6.5	6.5	6.3	
	6.0 %	5.8 %	5.8 %	6.0 %	5.8 %	4.3 %	4.3 %	4.2 %	4.1 %	4.0 %	3.8 %	3.7 %	3.5 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in Liquidity from														
- Working Capital	-0.9	1.5	3.1	1.8	2.6	2.7	2.4	2.5	2.6	2.2	2.3	2.4	1.1	
- Capex	3.3	4.3	5.8	5.0	5.0	5.2	5.2	5.4	5.7	5.9	6.2	7.9	7.4	
Capex in % of Sales	3.5 %	4.2 %	5.2 %	4.1 %	3.9 %	3.8 %	3.6 %	3.6 %	3.6 %	3.6 %	3.6 %	4.4 %	4.1 %	
- Other	0.0	0.0	0.0	-1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free Cash Flow (WACC Model)	3.1	2.1	2.7	9.3	10.7	10.0	11.2	11.7	12.1	12.9	13.1	11.9	13.8	14
PV of FCF	3.1	2.0	2.3	7.4	7.9	6.8	7.1	6.8	6.6	6.5	6.1	5.1	5.5	92
share of PVs	4.48 %			40.02 %						55.50 %				

Model parameter

Derivation of WACC:	Derivation of Beta:
Debt ratio	30.00 %
Cost of debt (after tax)	2.6 %
Market return	8.25 %
Risk free rate	2.75 %
WACC	7.91 %

Valuation (m)

Present values 2036/37e	73
Terminal Value	92
Financial liabilities	53
Pension liabilities	4
Hybrid capital	0
Minority interest	1
Market val. of investments	1
Liquidity	8
Equity Value	115
No. of shares (m)	6.1
Value per share (EUR)	19.01

Sensitivity Value per Share (EUR)

Terminal Growth							Delta EBIT-margin										
Beta	WACC	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.61	8.9 %	13.73	14.08	14.44	14.83	15.26	15.71	16.20	1.61	8.9 %	11.32	12.49	13.66	14.83	16.01	17.18	18.35
1.48	8.4 %	15.42	15.84	16.28	16.76	17.28	17.83	18.44	1.48	8.4 %	12.98	14.24	15.50	16.76	18.02	19.28	20.55
1.41	8.2 %	16.36	16.82	17.31	17.84	18.41	19.03	19.71	1.41	8.2 %	13.91	15.22	16.53	17.84	19.15	20.46	21.77
1.35	7.9 %	17.37	17.88	18.42	19.01	19.65	20.34	21.10	1.35	7.9 %	14.91	16.28	17.64	19.01	20.37	21.74	23.11
1.29	7.7 %	18.46	19.02	19.62	20.28	20.99	21.77	22.63	1.29	7.7 %	16.00	17.43	18.85	20.28	21.70	23.13	24.55
1.22	7.4 %	19.63	20.25	20.93	21.66	22.46	23.34	24.31	1.22	7.4 %	17.19	18.68	20.17	21.66	23.15	24.64	26.13
1.09	6.9 %	22.28	23.05	23.90	24.83	25.86	27.00	28.26	1.09	6.9 %	19.93	21.56	23.20	24.83	26.47	28.10	29.74

- Growth and mix improvements to drive return to higher profitability
- Disproportionately high growth of adhesive segment provides further upside potential
- Sustainable EBIT margin of 15% anticipated

Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Net Income before minorities	-4.9	-13.2	-10.9	-13.0	-1.4	0.9	4.2
+ Depreciation + Amortisation	13.5	6.3	9.8	13.4	5.6	6.0	6.6
- Net Interest Income	-1.0	-1.4	-1.6	-2.0	-1.8	-1.5	-1.2
- Maintenance Capex	2.5	2.6	3.0	3.0	3.0	3.0	3.0
+ Other	-0.4	-0.4	7.5	-1.3	0.0	0.0	0.0
= Free Cash Flow Potential	6.6	-8.5	5.0	-2.0	3.0	5.4	9.0
FCF Potential Yield (on market EV)	1.9 %	-3.5 %	2.9 %	-1.3 %	3.1 %	5.5 %	9.5 %
WACC	7.91 %	7.91 %	7.91 %	7.91 %	7.91 %	7.91 %	7.91 %
= Enterprise Value (EV)	353.1	239.9	169.7	156.4	98.0	96.9	94.8
= Fair Enterprise Value	83.9	n.a.	62.6	n.a.	37.9	67.7	113.3
- Net Debt (Cash)	45.7	45.7	45.7	45.7	43.9	42.8	40.7
- Pension Liabilities	4.4	4.4	4.4	4.4	4.4	4.4	4.4
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Market value of minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	33.8	n.a.	12.5	n.a.	n.a.	20.5	68.2
Number of shares, average	6.1	6.1	6.1	6.1	6.1	6.1	6.1
= Fair value per share (EUR)	5.58	n.a.	2.05	n.a.	n.a.	3.38	11.25
premium (-) / discount (+) in %						-58.8 %	37.2 %
Sensitivity Fair value per Share (EUR)							
WACC	10.91 %	1.77	n.a.	n.a.	n.a.	0.31	6.11
	9.91 %	2.78	n.a.	n.a.	n.a.	1.12	7.48
	8.91 %	4.02	n.a.	0.90	n.a.	2.12	9.15
	7.91 %	5.58	n.a.	2.05	n.a.	3.38	11.25
	6.91 %	7.58	n.a.	3.55	n.a.	4.99	13.95
	5.91 %	10.26	n.a.	5.55	n.a.	0.39	7.16
	4.91 %	14.04	n.a.	8.36	n.a.	2.09	10.20
							22.67

▪ Rising value indication triggered by margin expansion

Valuation

	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Price / Book	2.7 x	1.7 x	1.2 x	1.3 x	0.6 x	0.6 x	0.6 x
Book value per share ex intangibles	14.30	13.80	12.56	11.02	10.80	10.97	11.57
EV / Sales	3.1 x	2.1 x	1.6 x	1.6 x	1.0 x	1.0 x	0.8 x
EV / EBITDA	25.6 x	19.8 x	426.3 x	50.6 x	18.0 x	11.1 x	6.9 x
EV / EBIT	n.a.	41.1 x	n.a.	n.a.	n.a.	35.0 x	13.3 x
EV / EBIT adj.*	45.2 x	20.4 x	24.0 x	n.a.	n.a.	35.0 x	13.3 x
P / FCF	n.a.	n.a.	580.3 x	29.6 x	27.6 x	43.9 x	18.6 x
P / E	n.a.	n.a.	n.a.	n.a.	n.a.	68.3 x	12.4 x
P / E adj.*	111.1 x	n.a.	22.3 x	n.a.	n.a.	68.3 x	12.4 x
Dividend Yield	0.4 %	n.a.	n.a.	n.a.	n.a.	1.2 %	1.8 %
FCF Potential Yield (on market EV)	1.9 %	-3.5 %	2.9 %	-1.3 %	3.1 %	5.5 %	9.5 %

*Adjustments made for: -

Company Specific Items

	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Adj. FCFPS	-0.19	-0.83	2.51	3.07	2.77	2.66	2.92

Consolidated profit & loss



In EUR m	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Sales	115.2	116.1	106.3	98.7	93.5	102.0	112.5
Change Sales yoy	22.7 %	0.8 %	-8.4 %	-7.2 %	-5.3 %	9.1 %	10.3 %
Increase / decrease in inventory	3.1	1.7	-1.9	-1.5	0.0	0.0	0.0
Own work capitalised	0.0	0.4	0.1	0.0	0.2	0.0	0.1
Total Sales	118.3	118.2	104.5	97.3	93.7	102.0	112.6
Material expenses	48.9	54.8	51.1	39.3	35.2	38.3	41.1
Gross profit	69.3	63.4	53.3	58.0	58.4	63.8	71.5
<i>Gross profit margin</i>	<i>60.2 %</i>	<i>54.6 %</i>	<i>50.2 %</i>	<i>58.7 %</i>	<i>62.5 %</i>	<i>62.5 %</i>	<i>63.6 %</i>
Personnel expenses	39.7	39.7	39.5	41.3	40.7	42.0	43.9
Other operating income	1.6	3.6	3.3	2.2	1.7	1.8	1.8
Other operating expenses	17.5	15.2	16.7	15.8	14.0	14.8	15.8
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	13.8	12.1	0.4	3.1	5.4	8.7	13.7
<i>Margin</i>	<i>12.0 %</i>	<i>10.4 %</i>	<i>0.4 %</i>	<i>3.1 %</i>	<i>5.8 %</i>	<i>8.6 %</i>	<i>12.2 %</i>
Depreciation of fixed assets	9.0	5.6	5.4	5.1	5.0	5.4	6.0
EBITA	4.8	6.6	-5.0	-2.0	0.4	3.3	7.7
Amortisation of intangible assets	1.1	0.7	1.8	0.5	0.6	0.6	0.6
Goodwill amortisation	3.4	0.0	2.6	7.7	0.0	0.0	0.0
EBIT	0.3	5.8	-9.4	-10.3	-0.1	2.8	7.1
<i>Margin</i>	<i>0.3 %</i>	<i>5.0 %</i>	<i>-8.9 %</i>	<i>-10.4 %</i>	<i>-0.1 %</i>	<i>2.7 %</i>	<i>6.3 %</i>
EBIT adj.	7.8	11.7	7.1	0.0	-0.1	2.8	7.1
Interest income	0.1	0.1	0.2	0.1	0.1	0.0	0.0
Interest expenses	1.1	1.5	1.8	2.1	1.9	1.5	1.2
Other financial income (loss)	0.0	0.0	0.1	0.1	0.0	0.0	0.0
EBT	-0.7	4.4	-11.0	-12.2	-1.9	1.3	5.9
<i>Margin</i>	<i>-0.6 %</i>	<i>3.8 %</i>	<i>-10.3 %</i>	<i>-12.4 %</i>	<i>-2.1 %</i>	<i>1.3 %</i>	<i>5.2 %</i>
Total taxes	4.3	1.6	0.3	0.8	-0.6	0.4	1.7
Net income from continuing operations	-4.9	2.8	-11.3	-13.0	-1.4	0.9	4.2
Income from discontinued operations (net of tax)	0.0	-16.0	0.3	0.0	0.0	0.0	0.0
Net income before minorities	-4.9	-13.2	-10.9	-13.0	-1.4	0.9	4.2
Minority interest	0.0	0.2	0.2	0.3	0.2	0.2	0.2
Net income	-4.9	-13.4	-11.1	-13.3	-1.6	0.7	4.0
<i>Margin</i>	<i>-4.2 %</i>	<i>-11.5 %</i>	<i>-10.5 %</i>	<i>-13.5 %</i>	<i>-1.7 %</i>	<i>0.7 %</i>	<i>3.5 %</i>
Number of shares, average	6.1	6.1	6.1	6.1	6.1	6.1	6.1
EPS	-0.81	-2.20	-1.84	-2.19	-0.26	0.12	0.66
EPS diluted	-0.81	-2.20	-1.84	-2.19	-0.26	0.12	0.66

*Adjustments made for:


Guidance: 2025: Sales EUR 92-94; adj. EBITDA EUR 5-6m

Financial Ratios

	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Total Operating Costs / Sales	90.7 %	91.4 %	97.9 %	95.4 %	94.4 %	91.4 %	87.9 %
Operating Leverage	-4.3 x	2395.4 x	n.a.	-1.3 x	18.6 x	n.a.	15.2 x
EBITDA / Interest expenses	12.3 x	8.0 x	0.2 x	1.5 x	2.9 x	6.0 x	11.3 x
Tax rate (EBT)	-635.7 %	35.9 %	-2.5 %	-6.3 %	29.0 %	29.0 %	29.0 %
Dividend Payout Ratio	n.m.	0.0 %	0.0 %	0.0 %	0.0 %	64.7 %	21.7 %
Sales per Employee	175,297	176,971	181,471	170,222	155,833	159,375	175,781

Sales, EBITDA
in EUR mOperating Performance
in %

Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Assets							
Goodwill and other intangible assets	24.0	23.3	19.7	12.6	12.4	12.1	11.8
thereof other intangible assets	2.9	2.1	1.3	1.6	1.3	1.1	0.8
thereof Goodwill	21.1	21.1	18.4	11.0	11.0	11.0	11.0
Property, plant and equipment	87.8	79.6	75.1	71.6	69.6	68.2	67.7
Financial assets	1.1	1.1	1.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	112.9	103.9	95.8	84.3	82.0	80.4	79.6
Inventories	46.7	46.4	35.0	30.5	29.2	30.0	32.1
Accounts receivable	17.1	19.7	15.6	14.9	14.9	16.2	17.9
Liquid assets	12.1	7.1	9.3	7.5	8.6	4.7	6.8
Other short-term assets	14.1	18.4	20.3	18.2	18.0	17.8	16.8
Current assets	90.0	91.6	80.3	71.1	70.7	68.7	73.5
Total Assets	202.9	195.5	176.2	155.4	152.7	149.0	153.1
Liabilities and shareholders' equity							
Subscribed capital	6.1	6.1	6.1	6.1	6.1	6.1	6.1
Capital reserve	42.0	42.0	42.0	42.0	42.0	42.0	42.0
Retained earnings	62.7	58.8	47.8	31.4	29.8	30.6	33.9
Other equity components	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Shareholders' equity	110.7	106.9	95.8	79.4	77.9	78.6	82.0
Minority interest	0.4	0.4	0.3	0.3	0.3	0.3	0.3
Total equity	111.1	107.2	96.1	79.7	78.1	78.9	82.2
Provisions	9.3	4.7	3.6	4.7	4.7	4.7	4.7
thereof provisions for pensions and similar obligations	8.6	4.0	3.2	4.4	4.4	4.4	4.4
Financial liabilities (total)	53.5	59.4	56.8	53.2	52.5	47.5	47.5
Short-term financial liabilities	3.9	26.4	12.4	13.0	10.0	5.0	5.0
Accounts payable	9.4	10.3	7.6	6.4	6.0	6.6	7.3
Other liabilities	19.5	13.8	12.1	11.3	11.3	11.3	11.3
Liabilities	91.8	88.2	80.0	75.7	74.6	70.2	70.9
Total liabilities and shareholders' equity	202.9	195.5	176.2	155.4	152.7	149.0	153.1


Financial Ratios

	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Efficiency of Capital Employment							
Operating Assets Turnover	0.8 x	0.9 x	0.9 x	0.9 x	0.9 x	1.0 x	1.0 x
Capital Employed Turnover	0.7 x	0.7 x	0.7 x	0.8 x	0.7 x	0.8 x	0.9 x
ROA	-4.3 %	-12.9 %	-11.6 %	-15.8 %	-1.9 %	0.9 %	5.0 %
Return on Capital							
ROCE (NOPAT)	1.4 %	2.3 %	n.a.	n.a.	n.a.	1.6 %	4.0 %
ROE	-4.3 %	-12.3 %	-11.0 %	-15.2 %	-2.0 %	0.9 %	5.0 %
Adj. ROE	2.4 %	-6.9 %	5.3 %	-3.7 %	-2.0 %	0.9 %	5.0 %
Balance sheet quality							
Net Debt	50.1	56.3	50.7	50.1	48.3	47.2	45.1
Net Financial Debt	41.5	52.3	47.5	45.7	43.9	42.8	40.7
Net Gearing	45.1 %	52.5 %	52.7 %	62.9 %	61.9 %	59.9 %	54.9 %
Net Fin. Debt / EBITDA	300.7 %	431.5 %	n.a.	1480.5 %	808.2 %	489.9 %	297.9 %
Book Value / Share	18.3	17.6	15.8	13.1	12.8	13.0	13.5
Book value per share ex intangibles	14.3	13.8	12.6	11.0	10.8	11.0	11.6


ROCE Development



Net debt
in EUR m



Book Value per Share
in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Net income	-4.9	-13.4	-11.1	-13.3	-1.6	0.7	4.0
Depreciation of fixed assets	9.0	5.6	5.4	5.1	5.0	5.4	6.0
Amortisation of goodwill	3.4	0.0	2.6	7.7	0.0	0.0	0.0
Amortisation of intangible assets	1.1	0.7	1.8	0.5	0.6	0.6	0.6
Increase/decrease in long-term provisions	0.4	-0.2	-0.8	-0.1	0.0	0.0	0.0
Other non-cash income and expenses	2.1	5.1	7.2	3.0	0.2	0.2	1.0
Cash Flow before NWC change	11.2	-2.2	5.1	2.9	4.2	6.9	11.6
Increase / decrease in inventory	-12.5	-11.6	-1.8	2.7	1.3	-0.8	-2.1
Increase / decrease in accounts receivable	-1.3	-2.7	0.7	0.7	0.0	-1.3	-1.7
Increase / decrease in accounts payable	3.6	0.8	-0.9	-0.6	-0.4	0.6	0.7
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-10.2	-13.5	-1.9	2.8	0.9	-1.5	-3.1
Net cash provided by operating activities [1]	0.9	-15.7	3.1	5.7	5.1	5.4	8.5
Investments in intangible assets	-0.2	-0.1	-1.0	-0.7	-0.3	-0.3	-0.3
Investments in property, plant and equipment	-16.9	-5.2	-4.1	-3.0	-3.0	-4.0	-5.5
Payments for acquisitions	-7.7	0.0	0.0	-0.7	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.2	2.7	5.5	0.4	0.0	0.0	0.0
Net cash provided by investing activities [2]	-24.6	-1.7	2.6	-2.4	-3.3	-4.3	-5.8
Change in financial liabilities	4.3	4.9	-3.3	-4.8	-0.8	-5.0	0.0
Dividends paid	-3.0	-1.2	-0.1	-0.1	0.0	0.0	-0.6
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	1.2	3.7	-3.4	-4.9	-0.8	-5.0	-0.6
Change in liquid funds [1]+[2]+[3]	-22.5	-13.6	2.3	-1.6	1.1	-3.9	2.1
Effects of exchange-rate changes on cash	0.0	0.4	-0.2	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	11.7	-1.1	9.2	7.7	8.6	4.7	6.8

Financial Ratios


	2020/21	2021/22	2022/23	2023/24	2024/25e	2025/26e	2026/27e
Cash Flow							
FCF	-16.2	-20.0	0.2	3.6	1.8	1.1	2.7
Free Cash Flow / Sales	-14.0 %	-17.3 %	0.2 %	3.6 %	1.9 %	1.1 %	2.4 %
Free Cash Flow Potential	6.6	-8.5	5.0	-2.0	3.0	5.4	9.0
Free Cash Flow / Net Profit	331.2 %	150.0 %	-1.8 %	-27.0 %	-114.8 %	153.7 %	67.1 %
Interest Received / Avg. Cash	0.6 %	0.7 %	2.4 %	0.6 %	1.2 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	2.2 %	2.7 %	3.1 %	3.8 %	3.6 %	2.9 %	2.6 %
Management of Funds							
Investment ratio	14.8 %	4.5 %	4.8 %	3.7 %	3.5 %	4.2 %	5.2 %
Maint. Capex / Sales	2.2 %	2.2 %	2.8 %	3.0 %	3.2 %	2.9 %	2.7 %
Capex / Dep	126.5 %	83.8 %	51.8 %	27.1 %	59.3 %	72.1 %	88.3 %
Avg. Working Capital / Sales	40.2 %	44.9 %	44.4 %	39.7 %	39.1 %	36.2 %	34.8 %
Trade Debtors / Trade Creditors	180.9 %	191.0 %	206.6 %	234.4 %	248.3 %	245.5 %	245.2 %
Inventory Turnover	1.0 x	1.2 x	1.5 x	1.3 x	1.2 x	1.3 x	1.3 x
Receivables collection period (days)	54	62	54	55	58	58	58
Payables payment period (days)	70	69	54	59	62	63	65
Cash conversion cycle (Days)	309	284	238	261	278	262	261

CAPEX and Cash Flow


in EUR m



Free Cash Flow Generation



Working Capital



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All **data and consensus estimates** have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Dr. Höne	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005157101.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	142	71
Hold	46	23
Sell	7	4
Rating suspended	4	2
Total	199	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	39	76
Hold	9	18
Sell	1	2
Rating suspended	2	4
Total	51	100

PRICE AND RATING HISTORY DR. HÖNLE AS OF 15.09.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode +49 40 3282-2678
 Head of Equities mrode@mmwarburg.com

RESEARCH

Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Robert-Jan van der Horst Technology	+49 40 309537-290 rvanderhorst@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com		
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com		
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com		
Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com		
Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com		

INSTITUTIONAL EQUITY SALES

Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com	Leyan Ilkbahar Roadshow/Marketing	+49 40 3282-2695 ilkbahar@mmwarburg.com
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Jens Buchmüller Scandinavia, Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
Matthias Fritsch United Kingdom, Ireland	+49 40 3282-2696 mfritsch@mmwarburg.com		
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com		
Sascha Propp France	+49 40 3282-2656 spropp@mmwarburg.com		

SALES TRADING

Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bquast@mmwarburg.com
Christian Salomon Sales Trading	+49 40 3282-2685 csalomon@mmwarburg.com

DESIGNATED SPONSORING

Sebastian Schulz Designated Sponsoring	+49 40 3282-2631 sschulz@mmwarburg.com
Jörg Treptow Designated Sponsoring	+49 40 3282-2658 jtreptow@mmwarburg.com

MACRO RESEARCH

Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
--	--	---	--

Our research can be found under:

Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		

For access please contact:

Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
---	--	---	---